Drug
Zenapax
Zenapax is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Prevention of Diabetes Progression Trial (PDPT)
NCT00198146
completedphase_2
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
NCT00181142
completedphase_3
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
NCT00048152
completedphase_2
Zenapax to Treat Multiple Sclerosis
NCT00001934
Clinical Trials (4)
Showing 4 of 4 trials
NCT00198146Phase 2
Prevention of Diabetes Progression Trial (PDPT)
NCT00181142Phase 2
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
NCT00048152Phase 3
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
NCT00001934Phase 2
Zenapax to Treat Multiple Sclerosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4